No one should face hereditary cancer alone.

Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.

Hereditary Cancer Info > Cancer Treatment > Ovarian Cancer Treatment

Toggle Menu

Ovarian Cancer Treatment

There are many options for treating hereditary cancers. Choice of treatment can be personalized based on cancer type, stage and genetics.

PARP inhibitors for ovarian cancer

PARP inhibitors for ovarian cancer

Three PARP inhibitors have been approved by the FDA for treating ovarian, primary peritoneal and fallopian tube cancer.  

  • Lynparza (also known as olaparib
  • Rubraca (also known as rucaparib)
  • Zejula (also known as niraparib)

PARP inhibitors for advanced ovarian cancer

Lynparza is a PARP inhibitor approved by the FDA to treat ovarian, fallopian tube, and primary peritoneal cancer in women who carry mutations in BRCA1 or BRCA2, and who have received three or more previous lines of chemotherapy. 

Rubraca is a PARP inhibitor that was approved by the FDA to treat women with advanced ovarian, fallopian tube, and primary peritoneal cancer who have had two or more prior treatment and who have inherited mutations in BRCA or whose tumors have BRCA mutations as detected by the FoundationFocus CDxBRCA companion diagnostic test.

PARP inhibitors for maintenance therapy 

Maintenance therapy is a type of treatment that is given after initial standard treatment has been completed to try to keep the cancer from returning. The goal of maintenance therapy is to extend the length of time before a new recurrence emerges or even to turn a temporary remission into a long-term cure. Three PARP inhibitors have been FDA approved for use as maintenance therapy in women with ovarian, fallopian tube and primary peritoneal cancer. 

Lynparza has received FDA approval for use as a maintenance therapy after first-line of chemotherapy. This approval applies to women with a BRCA1 or BRCA2 mutation who experienced complete or partial response to their first-line platinum-based chemotherapy. This is based on the results of the SOLO1 Study which showed that patients who used Lynparza as a maintenance therapy immediately following chemotherapy had three additional years of progression-free survival (PFS) compared to a placebo.

Lynparza or Zejula may also be used as maintenance therapy for women with ovarian cancer regardless of mutation status, who have received 2 or more lines of chemotherapy who had either a complete or partial response to the most recent line of recurrence therapy. Rucaparib may be used as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Although these PARP inhibitors have been approved for maintenance therapy in women with, and women without a BRCA mutation, the research suggests that the agents work particularly well in women with a BRCA1 or BRCA2 mutation. 

PARP inhibitors as combination therapy

Research is now also looking at PARP inhibitor effectiveness when combined with other agents, such as drugs that shrink blood supply and immunotherapies. You can look for research studies enrolling women with hereditary ovarian, fallopian tube, and primary peritoneal cancer by visiting FORCE's Research Study Search Tool.

Updated 01/16/2019

FORCE:Facing Our Risk of Cancer Empowered